Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 401–500 of 1,016
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 86
“Combination treatment with ipilimumab plus nivolumab has been tested in melanoma, renal cell cancer, and lung cancer with and without high mutational burden (18,24,38).”
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 87
Giordan, Q., Salleron, J., Vallance, C., Moriana, C., & Clément-Duchêne, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716317 · Cited by 84
“ATB, Antibiotics; PPI, Proton-pump inhibitors; NSCLC, Nonsmall-cell lung carcinoma; RCC, Renal Cell Carcinoma; ICI, immune checkpoint inhibitors; PD-L1, programmed cell death-ligand 1; PS, performance status; NC, not calculated.”
BackgroundInfluentialPhase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer
Hannan, R., Christensen, M., Hammers, H. J., Christie, A. L., Paulman, B., Lin, D., Garant, A., Arafat, W., Courtney, K. D., Bowman, I. A., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2021.12.001 · Cited by 82
“2 mo for ipilimumab/nivolumab [2], 15.”
Self-citationA transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma
Alchahin, A. M., Mei, S., Τσέα, Ι., Hirz, T., Kfoury, Y. S., Dahl, D. M., Wu, C., Subtelny, A. O., Wu, S., Scadden, D. T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33375-w · Cited by 93
Ernst, M. S., Navani, V., Wells, J. C., Donskov, F. N., Basappa, N. S., Labaki, C., Pal, S. K., Meza, L., Wood, L. A., Ernst, D. S., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.01.001 · Cited by 82
Self-citationPembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
Tucker, M. D., Zhu, J., Marin, D., Gupta, R. T., Gupta, S. K., Berry, W. R., Ramalingam, S., Zhang, T., Harrison, M. R., Wu, Y. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2375 · Cited by 85
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma
Cotta, B. H., Choueiri, T. K., Cieslik, M. P., Ghatalia, P., Mehra, R., Morgan, T. M., Palapattu, G. S., Shuch, B. M., Vaishampayan, U. N., Allen, E. M. V., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.04.003 · Cited by 95
Self-citationImmune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Flippot, R., Escudier, B. J., & Albiges, L. K. (2018) · Drugs · doi:10.1007/s40265-018-0970-y · Cited by 81
“Combination therapies, however, might be accountable for more severe and more frequent irAEs, with grade 3–5 irAEs occurring in up to 50% of patients [30, 33, 71].”
BackgroundMethodSelf-citationMassari, F., Mollica, V., Rizzo, A., Cosmai, L., Rizzo, M., & Porta, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1811226 · Cited by 81
Self-citationOphthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Fortes, B. H., Liou, H., & Dalvin, L. A. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316970 · Cited by 81
Renal cell carcinoma therapy: Current and new drug candidates
Pontes, O., Oliveira-Pinto, S., Baltazar, F., & Costa, M. F. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.009 · Cited by 85
Albiges, L. K., Tannir, N. M., Burotto, M., McDermott, D. F., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T. B., Donskov, F. N., George, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.10.001 · Cited by 84
Self-citationImmune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Jessel, S., Weiss, S. A., Austin, M., Mahajan, A. K., Etts, K., Zhang, L., Aizenbud, L., Perdigoto, A. L., Hurwitz, M. E., Sznol, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836859 · Cited by 86
“However, this may have been mostly impacted by the fact that only treatment-related AEs that occurred in >15% of patients were reported (29, 30) and this would likely exclude hypophysitis.”
BackgroundCacciotti, C., Choi, J. J., Alexandrescu, S., Zimmerman, M. A., Cooney, T. M., Chordas, C. A., Clymer, J. R., Chi, S. N., & Yeo, K. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03578-6 · Cited by 84
Dumont, C., Jacquier, A., Verine, J., Noël, F., Goujon, A., Wu, C., Hung, T., Desgrandchamps, F., Culine, S., Carosella, E. D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0764 · Cited by 89
“PD-1 antibodies are effective in multiple cancer types, albeit only in a subset of patients, as exemplified by metastatic renal cell carcinoma (mRCC): the PD-1 antibody nivolumab (1) is effective in about one-fourth of patients with pretreated mRCC, and the combination of nivolumab with the CTLA-4 antibody ipilimumab…”
BackgroundKanaya, N., Kuroda, S., Kakiuchi, Y., Kumon, K., Tsumura, T., Hashimoto, M., Morihiro, T., Kubota, T., Aoyama, K., Kikuchi, S., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.003 · Cited by 88
Borel, C., Jung, A. C., & Burgy, M. (2020) · Cancers · doi:10.3390/cancers12092691 · Cited by 83
Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review
Dahle, D. O., Skauby, M., Langberg, C. W., Brabrand, K., Wessel, N., & Midtvedt, K. (2021) · Transplantation · doi:10.1097/tp.0000000000003762 · Cited by 83
Dual targeting of CTLA-4 and CD47 on T reg cells promotes immunity against solid tumors
Zhang, A., Ren, Z., Tseng, K., Liu, X., Li, H., Lu, C., Cai, Y., Minna, J. D., & Fu, Y. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8693 · Cited by 81
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Kim, M., Jin, Z., Kolb, R. H., Borcherding, N. C., Chatzkel, J. A., Falzarano, S. M., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13225856 · Cited by 87
“ICI monotherapy showed 25 to 42% response rates in ccRCC patients [15,21].”
BackgroundPrognostication in Kidney Cancer: Recent Advances and Future Directions
Graham, J., Dudani, S., & Heng, D. Y. C. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0147 · Cited by 79
Park, R., da Silva, L. L., Cristancho, C., Riaño, I., & Saeed, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00258 · Cited by 79
“(13) RCC PD-1 + CTLA-4 NONE III N3I1 15 4 547”
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Alaiwi, S. A., Nassar, A. H., Xie, W., Bakouny, Z., Berchuck, J. E., Braun, D. A., Baca, S. C., Nuzzo, P. V., Flippot, R., Mouhieddine, T. H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0866 · Cited by 87
Self-citationWang, C., Shi, X., Song, H., Zhang, C., Wang, X., Huang, P., Dong, A., Zhang, Y., Kong, D., & Wang, W. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120579 · Cited by 78
Riaz, I. B., He, H., Ryu, A. J., Siddiqi, R. L., Naqvi, S. A. A., Yao, Y., Husnain, M., Narasimhulu, D. M., Mathew, J., Sipra, Q. U. A. R., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.016 · Cited by 86
Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
Boumber, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.120 · Cited by 79
Vento, J. A., Mulgaonkar, A., Woolford, L., Nham, K., Christie, A. L., Bagrodia, A., de Leon, A. D., Hannan, R., Bowman, I. A., McKay, R. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0607-z · Cited by 77
Tumors vs. Chronic Wounds: An Immune Cell's Perspective
Hua, Y., & Bergers, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02178 · Cited by 89
“Interestingly, the mutational rate and neoantigen burden of tumors did not correlate with progression-free survival (PFS), but angiogenesis and myeloid inflammatory gene expression signatures associated strongly with PFS within and across the treatments arguing that these signatures could be utilized as prospective bi…”
Backgroundde Cubas, A. A., Dunker, W., Zaninovich, A., Hongo, R. A., Bhatia, A., Panda, A., Beckermann, K. E., Bhanot, G., Ganesan, S., Karijolich, J. J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137569 · Cited by 84
“The development of immune checkpoint blockade (ICB) for the clinical management of ccRCC has achieved remarkable success in subsets of patients (1, 2).”
BackgroundIacovelli, R., Ciccarese, C., Bria, E., Sergio Bracarda, A., Porta, C., Procopio, G., & Tortora, G. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.008 · Cited by 76
Self-citationKhaddour, K., Johanns, T. M., & Ansstas, G. (2020) · Pharmaceuticals · doi:10.3390/ph13110389 · Cited by 80
Mollica, V., Santoni, M., Matrana, M. R., Basso, U., Giorgi, U. D., Rizzo, A., Maruzzo, M., Marchetti, A., Rosellini, M., Bleve, S., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00861-y · Cited by 82
Toxicity in the era of immune checkpoint inhibitor therapy
Keam, S., Turner, N., Kugeratski, F. G., Rico, R., Colunga-Minutti, J., Poojary, R., Alekseev, S., Patel, A. B., Li, Y. J., Sheshadri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447021 · Cited by 92
Signoretti, S., Flaifel, A., Chen, Y., & Reuter, V. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2259 · Cited by 76
“and is now approved by Food and Drug Administration for the treatment of intermediate or poor risk previously untreated patients.(60) Despite these important advances, only a minority of patients with metastatic RCC (mRCC) who receive either targeted agents or immune checkpoint inhibitors respond to a given treatment.”
BackgroundMeyers, D. E., Stukalin, I., Vallerand, I. A., Lewinson, R. T., Suo, A. E., Dean, M. L., North, S. A., Pabani, A., Cheng, T., Heng, D. Y. C., et al. (2019) · Cancers · doi:10.3390/cancers11111713 · Cited by 80
“The efficacy of ICI has clearly been demonstrated in a number of phase III randomized control trials in non-small cell lung cancer (NSCLC) [1,2], renal cell carcinoma (RCC) [3,4], and melanoma [5].”
BackgroundShimozaki, K., Sukawa, Y., Beppu, N., Kurihara, I., Suzuki, S., Mizuno, R., Funakoshi, T., Ikemura, S., Tsugaru, K., Togasaki, K., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s247554 · Cited by 83
Krishnamoorthy, M., Lenehan, J. G., & Vareki, S. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa216 · Cited by 76
“Immune checkpoint inhibitors (ICIs) used as a single agent or in combination with other types of ICIs or chemotherapy has markedly improved patient outcomes in advanced and metastatic settings (3-7).”
BackgroundThe ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes
Lees, J. S., Elyan, B. M. P., Herrmann, S. M., Lang, N. N., Jones, R. J., & Mark, P. B. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac011 · Cited by 77
Neutrophil Extracellular Traps in Cancer Therapy Resistance
Shahzad, M. H., Feng, L., Su, X., Brassard, A., Dhoparee‐Doomah, I., Ferri, L. E., Spicer, J. D., & Cools‐Lartigue, J. (2022) · Cancers · doi:10.3390/cancers14051359 · Cited by 81
Kim, C. M., Lee, J. B., Shin, S. J., Ahn, J. B., Lee, M., & Kim, H. S. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100577 · Cited by 83
“This study reports meta-regression and more comprehensive analysis of ICIs using the data obtained from 30 RCTs with updated search (included recently published 17 trials(3,25-36,38-41)) and the inclusion of 6 trials of anti-CTLA4.(29,35,41,45,52,53) Furthermore, data collected from >17 000 patients and robust quality…”
BackgroundMethodRini, B. I., Signoretti, S., Choueiri, T. K., McDermott, D. F., Motzer, R. J., George, S., Powles, T. B., Donskov, F. N., Tykodi, S. S., Pal, S. K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005445 · Cited by 83
Self-citationZhao, Y., Ma, Y., Fan, Y., Zhou, J., Yang, N., Yu, Q., Zhuang, W., Song, W., Wang, Z. M., Li, B., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107355 · Cited by 81
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
Cherny, N. I., Oosting, S. F., Dafni, U. G., Latino, N. J., Galotti, M., Zygoura, P., Dimopoulou, G., Amaral, T. M. S., Barriuso, J., Calles, A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.04.006 · Cited by 81
Stenzel, P., Schindeldecker, M., Tagscherer, K. E., Foersch, S., Herpel, E., Hohenfellner, M., Hatiboglu, G., Alt, J., Thomas, C., Haferkamp, A., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.11.002 · Cited by 86
“Furthermore, recently a randomized phase 3 study with nivolumab combined with ipilimumab, targeting immune checkpoint protein cytotoxic T-lymphocyte (CTL)eassociated protein 4, showed significantly higher OS and response rates compared with sunitinib among intermediate- and poor-risk patients with previously untreated…”
BackgroundEsser, L. K., Branchi, V., Leonardelli, S., Pelusi, N., Simon, A. G., Klümper, N., Ellinger, J., Hauser, S., Gonzalez-Carmona, M. A., Ritter, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01775 · Cited by 75
“Thus, ICI blocking PD-1/PD-L1 became standard of cares in treatment-naïve and pre-treated patients with ccRCC (5, 6).”
BackgroundMethodSeeber, A., Klinglmair, G., Fritz, J., Steinkohl, F., Zimmer, K., Aigner, F., Horninger, W., Gastl, G., Zelger, B., Brunner, A., et al. (2018) · Cancer Science · doi:10.1111/cas.13560 · Cited by 71
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 78
“Conversely, an improvement in ORR and OS for immunotherapy over the anti-vascular agent was reported independently from the tumor PD-L1 expression level, even though the magnitude of benefit was higher in patients with PD-L1 ≥1% (13).”
BackgroundTakamatsu, K., Tanaka, N., Hakozaki, K., Takahashi, R., Teranishi, Y., Murakami, T., Kufukihara, R., Niwa, N., Mikami, S., Shinojima, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25865-0 · Cited by 84
Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis
Li, M., Wong, D., Vogel, A. S., Sack, J. S., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S. (2022) · Hepatology · doi:10.1002/hep.32215 · Cited by 73
Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 85
“CTLA-4 blockade has shown durable results in many types of cancer including melanoma, NSCLC, and renal cell carcinoma (RCC), possibly secondary to intratumoral Treg depletion [75, 96, 97].”
Stereotactic Ablative Radiation for Systemic Therapy–naïve Oligometastatic Kidney Cancer
Hannan, R., Christensen, M., Christie, A. L., Garant, A., Pedrosa, I., Robles, L., Mannala, S., Wang, C., Hammers, H. J., Arafat, W., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.06.008 · Cited by 73
Self-citationWang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 111
Chen, L., Zhu, D., Feng, J., Zhou, Y., Wang, Q., Feng, H., Zhang, J., & Jiang, J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0813-2 · Cited by 73
Deciphering Immune-Associated Genes to Predict Survival in Clear Cell Renal Cell Cancer
Hu, D., Zhou, M., & Zhu, X. (2019) · BioMed Research International · doi:10.1155/2019/2506843 · Cited by 86
“Although systemic adjuvant therapy received limited effects on prognosis of advanced ccRCC, nivolumab, as a programmed death 1 (PD-1) immune checkpoint inhibitor antibody, demonstrated promising improved survival outcome in the metastatic ccRCC [5, 6].”
BackgroundImmunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 76
Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors
Akbari, P., Katsarou, A., Daghighian, R., van Mil, L. W. H. G., Huijbers, E. J. M., Griffioen, A. W., & van Beijnum, J. R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188701 · Cited by 74
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
Meng, L., Collier, K. A., Wang, P., Li, Z., Monk, P., Mortazavi, A., Hu, Z., Spakowicz, D. J., Zheng, L., & Yang, Y. (2023) · Cells · doi:10.3390/cells13010034 · Cited by 86
“These pivotal findings have underpinned guidelines endorsing nivolumab/ipilimumab as a first-line therapy for intermediate/poor-risk metastatic ccRCC [60].”
BackgroundLucas, C. G., Mirchia, K., Seo, K., Najem, H., Chen, W., Zakimi, N., Foster, K. J., Eaton, C. D., Cady, M. A., Choudhury, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01747-1 · Cited by 79
Fukuda, S., Saito, K., Yasuda, Y., Kijima, T., Yoshida, S., Yokoyama, M., Ishioka, J., Matsuoka, Y., Kageyama, Y., & Fujii, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001564 · Cited by 71
Schenkel, L. B., Molina, J. R., Swinger, K. K., Abo, R., Blackwell, D. J., Lu, A. Z., Cheung, A. E., Church, W. D., Kunii, K., Kuplast-Barr, K. G., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.010 · Cited by 76
Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement
Chin, A. L., Jiang, S., Jang, E., Niu, L., Li, L., Jia, X., & Tong, R. (2021) · Nature Communications · doi:10.1038/s41467-021-25391-z · Cited by 76
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Capitanio, U., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 82
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 90
Gupta, S., Cheville, J. C., Jungbluth, A. A., Zhang, Y., Zhang, L., Chen, Y., Tickoo, S. K., Fine, S. W., Gopalan, A., Al‐Ahmadie, H. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0269-x · Cited by 76
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 78
“How quickly and widely the combination will be adopted in light of the positive results from randomized trials on malignancies that can be readily treated with other options [356,357], remains to be seen.”
Sanseviero, E., O’Brien, E. M., Karras, J. R., Shabaneh, T. B., Aksoy, B. A., Xu, W., Zheng, C., Yin, X., Xu, X., Karakousis, G. C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0386 · Cited by 80
Cui, H., Shan, H., Miao, M. Z., Jiang, Z., Meng, Y., Chen, R., Zhang, L., & Liu, Y. U. (2020) · Scientific Reports · doi:10.1038/s41598-020-61162-4 · Cited by 76
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma
Tenold, M. E., Ravi, P. K., Kumar, M., Bowman, I. A., Hammers, H. J., Choueiri, T. K., & Lara, P. N. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279881 · Cited by 77
Self-citationMcGregor, B. A., Lalani, A. A., Xie, W., Steinharter, J. A., Bakouny, Z., Martini, D. J., Fleischer, J. H., Alaiwi, S. A., Nassar, A. H., Nuzzo, P. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.009 · Cited by 71
Self-citationThe Evolution of STING Signaling and Its Involvement in Cancer
Vashi, N., & Bakhoum, S. F. W. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.12.010 · Cited by 72
Osteosarcoma: Current Concepts and Evolutions in Management Principles
Pilavaki, P., Ardakani, A. H. G., Gikas, P. D., & Constantinidou, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082785 · Cited by 81
“Immunotherapy, a rapidly evolving area in oncology, has been applied with success in several malignancies including melanoma [14], non-small cell lung cancer [15,16], and renal cell carcinoma [17].”
BackgroundZhao, Y., Ma, Y., Zang, A., Cheng, Y., Zhang, Y., Wang, X., Chen, Z., Qu, S., He, J., Chen, C., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01445-1 · Cited by 75
“3% in malignant pleural mesothelioma [25], 46% in renal cell carcinoma [26], and 59% in melanoma [27].”
BackgroundIndoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy
Yentz, S. E., & Smith, D. C. (2018) · BioDrugs · doi:10.1007/s40259-018-0291-4 · Cited by 70
Nunes‐Xavier, C. E., Angulo, J. C., Pulido, R., & Lopez, J. I. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0866-8 · Cited by 80
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
Brain Metastasis Organotropism
Yuzhalin, A. E., & Yu, D. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037242 · Cited by 75
Oft, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101325 · Cited by 77
Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 83
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
Hsieh, C.-H., Jian, C.-Z., Lin, L., Low, G.-S., Ou, P.-Y., Hsu, C., & Ou, D. (2022) · Cancers · doi:10.3390/cancers14020294 · Cited by 73
“3% [137], and the risk is lower than conventional therapy, such as 0–4% with targeted therapies [138] and about 15% with allogeneic hematopoietic stem cell transplantation [139].”
BackgroundSoluble PD-L1 as an early marker of progressive disease on nivolumab
Mahoney, K. M., Ross‐Macdonald, P., Yuan, L., Song, L., Veras, E., Wind‐Rotolo, M., McDermott, D. F., Hodi, F. S., Choueiri, T. K., & Freeman, G. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003527 · Cited by 76
Self-citationRecent advances and future perspectives in the therapeutics of prostate cancer
Varaprasad, G. L., Gupta, V., Prasad, K., Kim, E., Tej, M. B., Mohanty, P., Verma, H. K., Raju, G. S. R., Bhaskar, L. V., & Huh, Y. S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00444-9 · Cited by 80
“The synergistic effect of anti-D-1/PD-L1 and anti-CTLA-4 has been reported in renal cancer and melanoma [204, 205].”
BackgroundRenal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
Pichler, R., Compérat, É., Klatte, T., Pichler, M., Loidl, W. C., Lusuardi, L., & Schmidinger, M. (2019) · Cancers · doi:10.3390/cancers11030422 · Cited by 69
“In addition, the retrospective subgroup analysis of 112 sRCC intermediate or poor-risk patients from the CheckMate214 study [25] confirmed a higher rate of PD-L1 expression (≥1%) in sRCC than in non-sRCC (47–53% vs.”
ResultGupta, R., Ornstein, M. C., Li, H., Allman, K. D., Wood, L. S., Gilligan, T. D., Garcia, J. A., von Merveldt, D., Hammers, H. J., & Rini, B. I. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.11.012 · Cited by 69
Self-citationCombination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
Escudier, B. J. (2019) · New England Journal of Medicine · doi:10.1056/nejme1900887 · Cited by 69
Self-citationEfficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
Escudier, B. J., Motzer, R. J., Tannir, N. M., Porta, C., Tomita, Y., Maurer, M., McHenry, M. B., & Rini, B. I. (2019) · European Urology · doi:10.1016/j.eururo.2019.10.025 · Cited by 72
“Consortium (IMDC) intermediate- or poor-risk aRCC [1].”
BackgroundMethodSelf-citationYu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 73
Yip, S., Wells, J. C., Moreira, R. B., Wong, A., Srinivas, S., Beuselinck, B., Porta, C., Sim, H., Ernst, D. S., Rini, B. I., et al. (2018) · Cancer · doi:10.1002/cncr.31595 · Cited by 68
Self-citationZahoor, H., Barata, P. C., Jia, X., Martin, A. M., Allman, K. D., Wood, L. S., Gilligan, T. D., Grivas, P. D., Ornstein, M. C., Garcia, J. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0425-8 · Cited by 67
Self-citationZhang, X., Yin, X., Zhang, H., Sun, G., Yang, Y., Chen, J., Zhu, X., Zhao, P., Zhao, J., Liu, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5578-4 · Cited by 70
“FDA as the standard second-line treatment for mRCC and even in the first-line for moderate to high risk of mRCC [8, 9].”
Ishihara, H., Tachibana, H., Takagi, T., Kondo, T., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., Okumi, M., Ishida, H., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00660-6 · Cited by 71
The Changing Therapeutic Landscape of Metastatic Renal Cancer
Angulo, J. C., & Shapiro, O. (2019) · Cancers · doi:10.3390/cancers11091227 · Cited by 75
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson, L. M., Howard, J. E. F., Cruz, J. L. G., Jackson, C. C., Barnett, C. M. E., Overton, L., Liu, H. Y.-H., Ladwa, R., Simpson, F., McGrath, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32869 · Cited by 67
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 77
“the VEGF signaling inhibitor sunitinib in previously untreated advanced renal cell carcinoma (RCC) so far showed so far minimal toxicities and a reduction of the frequency of Tregs [NCT02231749, CheckMate 214, (34)].”
BackgroundNagaoka, K., Shirai, M., Taniguchi, K., Hosoi, A., Sun, C., Kobayashi, Y., Maejima, K., Fujita, M., Nakagawa, H., Nomura, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001358 · Cited by 75
Chyuan, I., Chu, C., & Hsu, P. (2021) · Cancers · doi:10.3390/cancers13061188 · Cited by 70
“Furthermore, CheckMate 214, another phase III clinical trial, reported no benefits in survival across PD-L1 levels under nivolumab–ipilimumab combination therapy for renal cell carcinoma [32].”
BackgroundHegewisch‐Becker, S., Mendez, G. A., Chao, J., Němeček, R., Feeney, K., Cutsem, E. V., Al‐Batran, S., Mansoor, W., Maisey, N. R., Pazo-Cid, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01636 · Cited by 73
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 77
Carneiro, A., Wroclawski, M. L., Nahar, B., Soares, A., Cardoso, A. P. G., Kim, N. J., & de Carvalho, F. R. T. (2020) · International braz j urol · doi:10.1590/s1677-5538.ibju.2020.04.03 · Cited by 66
“If not available, the choice between the combination of immunotherapy with ipilimumab and nivolumab versus TKI should take into account the risk of complications and potential readmissions (33).”
BackgroundUnderstanding genomics and the immune environment of penile cancer to improve therapy
Aydın, A. M., Chahoud, J., Adashek, J. J., Azizi, M., Magliocco, A. M., Ross, J. S., Necchi, A., & Spiess, P. E. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0359-z · Cited by 70
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.